Details
Titel in Übersetzung | The Meaning of Quality of Life with Rheumatoid Arthritis (RA) |
---|---|
Originalsprache | Mehrere Sprachen |
Seiten (von - bis) | 322-328 |
Seitenumfang | 7 |
Fachzeitschrift | Gesundheitsokonomie und Qualitatsmanagement |
Jahrgang | 9 |
Ausgabenummer | 5 |
Frühes Online-Datum | 27 Sept. 2004 |
Publikationsstatus | Veröffentlicht - Okt. 2004 |
Abstract
In recent years a number of novel substances have been introduced in the treatment of Rheumatoid Arthritis (RA). In the group of pain relieve drugs the group of coxib's should be mentioned above all, whom are believed in having a better risk profile with complications in the gastrointestinal area. The TNF-α antagonist's ethanercept, adalimumab and infliximab were added to the disease modifying drugs (DMARDs), which are designed to slow or stop a progression of RA. These new active substances are far more costly than comparators already in the market, which may be justified by a superior outcome, which is subject of a number of health economic evaluation studies to date. Those health-economic evaluations often try to model advantages of those novel substances in order to show the long-term effects on direct and indirect cost domains. The long term data needed for a high validity of the models is very limited. Therefore it is very important for medical groups in the field of RA, to learn more about certain aspects of the health related quality of life accompanied with different treatment regimens as a special field in health economics. Hence, we give the reader the methodical tools, so that results of quality of life studies in RA may be added and enrich the structure of health services given to patients in daily practice.
Schlagwörter
- Ambulatory care, Quality of life, Rheumatoid arthritis
ASJC Scopus Sachgebiete
- Medizin (insg.)
- Health policy
Ziele für nachhaltige Entwicklung
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: Gesundheitsokonomie und Qualitatsmanagement, Jahrgang 9, Nr. 5, 10.2004, S. 322-328.
Publikation: Beitrag in Fachzeitschrift › Übersichtsarbeit › Forschung › Peer-Review
}
TY - JOUR
T1 - Die Bedeutung der Lebensqualität bei Rheumatoider Arthritis (RA)
AU - Mittendorf, T.
AU - Greiner, W.
AU - Von Graf Der Schulenburg, J. M.
PY - 2004/10
Y1 - 2004/10
N2 - In recent years a number of novel substances have been introduced in the treatment of Rheumatoid Arthritis (RA). In the group of pain relieve drugs the group of coxib's should be mentioned above all, whom are believed in having a better risk profile with complications in the gastrointestinal area. The TNF-α antagonist's ethanercept, adalimumab and infliximab were added to the disease modifying drugs (DMARDs), which are designed to slow or stop a progression of RA. These new active substances are far more costly than comparators already in the market, which may be justified by a superior outcome, which is subject of a number of health economic evaluation studies to date. Those health-economic evaluations often try to model advantages of those novel substances in order to show the long-term effects on direct and indirect cost domains. The long term data needed for a high validity of the models is very limited. Therefore it is very important for medical groups in the field of RA, to learn more about certain aspects of the health related quality of life accompanied with different treatment regimens as a special field in health economics. Hence, we give the reader the methodical tools, so that results of quality of life studies in RA may be added and enrich the structure of health services given to patients in daily practice.
AB - In recent years a number of novel substances have been introduced in the treatment of Rheumatoid Arthritis (RA). In the group of pain relieve drugs the group of coxib's should be mentioned above all, whom are believed in having a better risk profile with complications in the gastrointestinal area. The TNF-α antagonist's ethanercept, adalimumab and infliximab were added to the disease modifying drugs (DMARDs), which are designed to slow or stop a progression of RA. These new active substances are far more costly than comparators already in the market, which may be justified by a superior outcome, which is subject of a number of health economic evaluation studies to date. Those health-economic evaluations often try to model advantages of those novel substances in order to show the long-term effects on direct and indirect cost domains. The long term data needed for a high validity of the models is very limited. Therefore it is very important for medical groups in the field of RA, to learn more about certain aspects of the health related quality of life accompanied with different treatment regimens as a special field in health economics. Hence, we give the reader the methodical tools, so that results of quality of life studies in RA may be added and enrich the structure of health services given to patients in daily practice.
KW - Ambulatory care
KW - Quality of life
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=6044270363&partnerID=8YFLogxK
U2 - 10.1055/s-2004-813648
DO - 10.1055/s-2004-813648
M3 - Review article
AN - SCOPUS:6044270363
VL - 9
SP - 322
EP - 328
JO - Gesundheitsokonomie und Qualitatsmanagement
JF - Gesundheitsokonomie und Qualitatsmanagement
SN - 1432-2625
IS - 5
ER -